Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. - Test2 - elhamkhani - TriplyDB

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33368885

about

Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia Alemtuzumab for chronic lymphocytic leukaemia Monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia Stem cell transplantation in chronic lymphocytic leukemia Fludarabine in the treatment of chronic lymphocytic leukemia: a review Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia Clinical implications of the molecular genetics of chronic lymphocytic leukemia Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia Pentostatin in chronic lymphocytic leukemia First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis.Autoimmune hemolytic anemias, Evans' syndromes, and pure red cell aplasia in non-Hodgkin lymphomas.Oblimersen for the treatment of patients with chronic lymphocytic leukemia.Alemtuzumab for B-cell chronic lymphocytic leukemia.A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.Autoimmune complications in chronic lymphocytic leukaemia (CLL).Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Autoimmune cytopenias in chronic lymphocytic leukemia.Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.The clinical significance of patients' sex in chronic lymphocytic leukemia.Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia.First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.Advances in treating chronic lymphocytic leukemia

P2860

Q24198941-6C23CB6B-6CD3-4495-A6FB-2B24821AA082 Q24203027-B453DDEA-04E3-4979-B744-8D99E5B58A4A Q24203628-12DA6388-ABAF-4CF7-B7DA-C63014F62950 Q24240922-30C1EFD3-5F5F-47EA-8AAE-3AF8E0F67DBF Q24241519-0E37E3A8-CC63-4679-AEE0-976DF253BB92 Q24617708-D53D8ABA-13D9-47A2-B46E-CD98B3867665 Q24642921-34887ACF-DBF9-43F8-AF9E-094F782D47B9 Q24645173-477560CC-3BA7-4AD0-8879-A177D2633015 Q24681296-883C85BC-5E57-4C94-BCCD-323C56855EA1 Q26781163-20C964F4-D926-4BCF-A066-6EC400D4B00C Q26830955-B30495D9-6953-45F9-A942-8149EABED281 Q27001163-8AA2E530-FD6A-4BE7-869C-80ADD8C438EE Q28082086-A1BD4850-11F8-4D37-96A1-4FF934D09747 Q28261949-4BC1EE48-E94A-42D1-B5F7-2B4084C5D6E7 Q28291531-44FDE692-4E86-42CF-9E6F-85D52A8B63C8 Q30891802-56F4D44C-72BA-45BA-B2BA-8DF26E04437B Q33375613-15DF5867-58E4-415E-8D5E-5FB19E032DB7 Q33379565-7EC2BE1B-550D-4655-BF9B-E4B63A29D4DB Q33380135-FFD22302-84C1-4CB1-A262-5FF17B32D1D9 Q33384219-F90C573E-3336-4E33-89FD-442DB5E84C7A Q33388795-CF4E89E6-FF5C-4F2F-9CD3-8826C1D9182D Q33390656-9DA2B641-DB3A-4407-81E9-76AC4877CBB7 Q33391919-3CF8D036-6671-4528-B941-2F963091030C Q33394947-15DD56A3-4753-414A-B18B-C6D09C701B5C Q33406478-39AFBC61-7C9C-4952-AA23-5BF32AC19017 Q33407866-589BBD53-6267-4E52-98A8-98157C0EAC0F Q33414468-BC5E72D8-6926-4232-B777-6999EE00B1DD Q33417548-1D63E1CA-7674-4168-89BE-1F1864DD2E8C Q33424781-D3383796-6C0E-4CD4-9B0A-5F4CE57CCC3D Q33558148-6AA4D865-8841-45C1-8065-64D202AD6A5A Q33573355-4F44F9D8-3124-4EDA-AC48-39FE5797A115 Q33695983-ABF240D7-4011-4129-A5AE-6A29CCC79FE6 Q33695990-8DD92DCD-B635-4398-AD8A-3E0627357673 Q33880538-6473CAFF-6E02-4EAD-B144-B65969AFFC3D Q33903379-A9E28B4B-4C4F-4C9A-ADB6-DCC3105AA574 Q33905245-B63DD078-E708-4374-B326-7A39DE8A57C3 Q33942272-E6E8D793-DB05-4916-96DD-BAA8354F7C66 Q33956034-1DEC6BC1-7B9B-46E1-9010-66C75C7331E5 Q34008866-74F6A228-1126-440E-9ED9-C34FA9AE6F0C Q34019917-309BAB82-B5C4-4EA5-85E1-128D00090578

P2860

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q33368885

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@ast

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@en

type

label

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@ast

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@en

prefLabel

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@ast

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@en

P1433

Q33368885-4B37C534-F86E-46D1-A38C-72DBDB6C7EA1

P1476

Q33368885-52AAD228-577D-431A-AA08-CC947FC28E03

P2093

Q33368885-0987A363-B393-4317-95B2-61C26F451082

Q33368885-1FDA1396-ABCE-4771-82A6-65760A490368

Q33368885-332B7B4D-1D46-4F75-8A21-1A01D9172458

Q33368885-337B8296-6B7D-46F3-BDDF-4A183FCAA83C

Q33368885-35308CFC-A6F1-4F98-A8B0-6AA2F54053EA

Q33368885-395DCEE9-6AF9-4B0F-A5C3-66543FD00F5E

Q33368885-3F5363F8-6D70-4B3E-9415-7879F93C5C10

Q33368885-45D23261-4590-4E54-8A7E-10D7E31C6229

Q33368885-7CFA5ED1-EFF4-4A53-827B-41665381B3BA

Q33368885-B01EBFF0-21D9-4473-ADFA-E5365DF51A5A

P304

Q33368885-0A4BB22A-DE06-4F11-988C-FA5E3A12B3DF

P31

Q33368885-72FE4334-FBE0-4ECB-A01C-72F33DCA6FBA

P356

Q33368885-D797D1FC-1B8D-4E36-913D-442B5837B828

P407

Q33368885-8E167F53-7EA5-452C-AD3B-AE327BB98D96

P433

Q33368885-259C8988-0D94-45C8-9396-781A1937EE93

P478

Q33368885-AE239DD4-4635-4DE8-964A-9D1E079CD0BE

P50

Q33368885-000B8E4B-8E1E-4736-BEB8-7864F9B39EAD

Q33368885-0633A126-846E-4373-BB84-EC78F25EF025

Q33368885-1FEDBE2B-EA1E-4AC3-A987-F5E4E90824F1

Q33368885-3F5E52B6-D57E-4A91-9F9B-77B077C0BD78

P577

Q33368885-4206B45D-7BA5-412E-8981-96E149F1FD30

P5875

Q33368885-9D8AB0BC-28D0-4AFC-A835-F1CC1A35AF54

P698

Q33368885-F9A0187D-ADAC-43F8-BF30-6079B184D71B

P921

Q33368885-79676DC1-376D-4369-942C-5FBC7292897B

Q33368885-B5C247A5-C773-42C8-85F0-FCB44E874411

P356

BLOOD-2005-06-2395

P1433

P1476

Fludarabine plus cyclophospham ...... chronic lymphocytic leukemia.

@en

P2093

Barbara F Eichhorst

http://www.w3.org/2001/XMLSchema#string

Bertold Emmerich

http://www.w3.org/2001/XMLSchema#string

Carmen Schweighofer

http://www.w3.org/2001/XMLSchema#string

Clemens M Wendtner

http://www.w3.org/2001/XMLSchema#string

Cordelia Steinbrecher

http://www.w3.org/2001/XMLSchema#string

Georg Hopfinger

http://www.w3.org/2001/XMLSchema#string

German CLL Study Group

http://www.w3.org/2001/XMLSchema#string

Günter Brittinger

http://www.w3.org/2001/XMLSchema#string

Manfred Hensel

http://www.w3.org/2001/XMLSchema#string

Manuela Bergmann

http://www.w3.org/2001/XMLSchema#string

P304

885-891

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-06-2395

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

German CLL Study Group

Stephan Stilgenbauer

Hartmut Döhner

P577

2005-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7545949

http://www.w3.org/2001/XMLSchema#string

P698

16219797

http://www.w3.org/2001/XMLSchema#string

P921